NCT02318329 2024-06-04
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Five Prime Therapeutics, Inc.
Phase 1 Completed
Clinical Trials
4 trialsNCT03343301 2024-02-28
FIGHT
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT03694522 2024-02-28
FIGHT
Five Prime Therapeutics, Inc.
Phase 2 Completed
NCT02213289 2021-04-08
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
University of Chicago
Phase 2 Completed